Order results by:
| Issue | Title | |
| Vol 7, No 2 (2015) | The fifth anniversary of clinical use of new oral anticoagulants in non-valvular atrial fibrillation | Abstract similar documents |
| A. V. Fonyakin | ||
| "... Administration (FDA) in the Medicare system. In the dabigatran group, the risk of ischemic stroke, intracranial ..." | ||
| Vol 11, No 3S (2019): Спецвыпуск: когнитивные нарушения, цереброваскулярные заболевания | Intracranial hemorrhage in patients taking oral anticoagulants. Current possibilities for therapy | Abstract similar documents |
| S. N. Yanishevsky | ||
| "... anticoagulants (NOACs) are used, but the hematoma evolution scenarios do not differ between the groups ..." | ||
| Vol 6, No 4 (2014) | Current guidelines and prospects for using novel oral anticoagulants for nonvalvular atrial fibrillation | Abstract similar documents |
| A. V. Fonyakin | ||
| "... anticoagulants (NOACs), such as dabigatran, rivaroxaban, and apixaban. World clinical experience with NOACs in AF ..." | ||
| Vol 5, No 2 (2013) | Dabigatran experience in primary and secondary prevention of cardioembolic stroke | Abstract similar documents |
| Maksim Alekseyevich Domashenko, M Yu Maksimova, D Z Korobkova, M E Gafarova | ||
| "... The review of novel oral anticoagulants (dabigatran, rivaroxaban and apixaban) in stroke prevention ..." | ||
| Vol 6, No 2 (2014) | Dabigatran etexilate for nonvalvular atrial fibrillation in real practice and promises for its use to prevent stroke | Abstract similar documents |
| A.V. Fonyakin | ||
| "... , one of which is dabigatran. A wealth of world clinical experience with dabigatran has confirmed its ..." | ||
| Vol 12, No 1 (2020) | The first experience with thrombolytic therapy for cerebral infarction in the Russian Federation after the use of idarucizumab | Abstract similar documents |
| E. V. Pudov, N. N. Sukhacheva, I. S. Petelina | ||
| "... fibrillation (AF) who took dabigatran 110 mg twice a day developed recurrent ischemic stroke (IS) that caused ..." | ||
| Vol 7, No 4 (2015) | Topical issues of the efficiency and safety of using the first direct thrombin inhibitor in real clinical practice | Abstract similar documents |
| A. V. Fonyakin | ||
| "... aspects of the efficiency and safety of using the first direct thrombin inhibitor dabigatran etexilate ..." | ||
| Vol 4, No 1 (2012) | New possibilities in the prevention of stroke in atrial fibrillation | Abstract similar documents |
| Vladimir Anatolyevich Parfenov, S V Verbitskaya | ||
| "... the efficacy of the new thrombin inhibitor dabigatran (pradax) in a dose of 150 or 110 mg twice daily ..." | ||
| Vol 8, No 4 (2016) | GLOBAL CLINICAL PRACTICE AND PERSONALIZED CHOICES FOR ORAL ANTICOAGULANT THERAPY FOR NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
| A. V. Fonyakin, L. A. Geraskina | ||
| "... in the Medicare system have indicated that treatment with dabigatran 150 mg versus rivaroxaban reduces the risk ..." | ||
| Vol 5, No 2S (2013): Special issue "Stroke" | Current approaches to antithrombotic therapy in patients with cardioembolic stroke | Abstract similar documents |
| Oleg Ivanovich Vinogradov, A N Kuznetsov, N V Rybalko | ||
| Vol 10, No 3 (2018) | Current strategies to improve the efficiency and safety of prevention and treatment of embolic stroke in non-valvular atrial fibrillation: possibilities of neutralizing therapy | Abstract similar documents |
| S. N. Yanishevsky | ||
| Vol 6, No 2S (2014): Special issue "Stroke" | Secondary prevention of stroke in atrial fibrillation, use of apixaban: ARISTOTLE, AVERROES studies | Abstract similar documents |
| V.A. Parfenov, S.V. Verbitskaya | ||
| "... – dabigatran. Presented results ARISTOTLE study, where have defined preference apixaban vs warfarin ..." | ||
| Vol 6, No 3 (2014) | The risk factors and prevention of stroke in atrial fibrillation | Abstract similar documents |
| V. A. Parfenov, S. V. Verbitskaya | ||
| "... randomized trials that show that novel oral anticoagulants (dabigatran, rivaroxaban, apixaban) are as good ..." | ||
| Vol 8, No 1 (2016) | Hemorrhagic stroke and oral anticoagulants: What is to be done? | Abstract similar documents |
| M. A. Domashenko | ||
| "... ) and novel oral anticoagulants (dabigatran. rivaroxaban, apixaban), as well as an anticoagulant resumption ..." | ||
| Vol 6, No 1 (2014) | Rivaroxaban in secondary prevention of cardioembolic stroke: standards and abnormal situations | Abstract similar documents |
| A.V. Fonyakin, L.A. Geraskina | ||
| "... практику новых пероральных антикоагулянтов (НОАК), одним из которых является ривароксабан. В реальной ..." | ||
| Vol 4, No 3 (2012) | A new era of anticoagulant therapy in the prevention of stroke in non-rheumatic atrial fibrillation | Abstract similar documents |
| Andrei Viktorovich Fonyakin, L A Geraskina | ||
| "... прямого ингибитора тромбина (дабигатрана этексилат) и прямые антагонисты фактора Ха (ривароксабан ..." | ||
| 1 - 16 of 16 Items | ||
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
